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In a phase I study we demonstrated the feasibility of a bi-weekly combination of paclitaxel 180 mg m
72 with cisplatin
60 mg m
72. In this study we further assessed toxicity and efﬁcacy of this schedule in the treatment of advanced cancer of the
oesophagus or the gastro-oesophageal junction. Patients received paclitaxel 180 mg m
72 administered over 3 h followed by a
3-h infusion of cisplatin 60 mg m
72. Patients were retreated every 2 weeks unless granulocytes were 50.75610
9 or platelets
575610
9. Patients were evaluated after three and six cycles and responding patients received a maximum of eight cycles.
Fifty-one patients were enrolled into the study. The median age was 56 years (range 32–78). WHO performance status
were: 0 (19 patients); 1 (29 patients); 2 (three patients). All patients received at least three cycles of chemotherapy and all
were evaluable for toxicity and response. Haematological toxicity consisted of uncomplicated neutropenia grade 3 in 39% and
grade 4 in 31% of patients. Five patients (10%) were hospitalised, three patients because of treatment related complications
and two patients because of infections without neutropenia. Sensory neurotoxicity was the predominant non-haematological
toxicity; grade 1 and 2 neurotoxicity was observed in 43 and 20% of patients, respectively. Response evaluation in 51 patients
with measurable disease: complete response 4%, partial response 39%, stable disease 43% and progressive disease in 14% of
the patients. The median duration of response was 8 months. The median survival for all patients was 9 (range 2–29+)
months and the one-year survival rate was 43%. Four patients who received additional local treatment (two patients surgery
and two patients radiotherapy) are still disease free after a follow-up of 20–29 months. This bi-weekly treatment of paclitaxel
and cisplatin is well tolerated by patients with advanced oesophageal cancer. The toxicity proﬁle of this regimen compares
favourable to that of previously used cisplatin- and paclitaxel-based regimens. Trials are underway evaluating this bi-weekly
regimen in a neo-adjuvant setting.
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The incidence of oesophageal cancer is rising in the United States
and most Northern European countries, especially due to a rapid
increase in the incidence of adenocarcinomas of the distal oesopha-
gus or the gastro-oesophageal junction (Blot and McLaughlin,
1999). Although adenocarcinomas are known to be related to
symptoms of gastric reﬂux (Lagergren et al, 1999) and to specialised
columnar (Barrett’s) epithelia (Jankowski et al, 1999) it is question-
able whether this totally accounts for the rising incidence.
Many patients who present with symptoms of oesophageal
obstruction already have locally advanced or metastatic disease.
After surgery the 5-year survival is 20% and the majority of
patients relapse both locoregionally as well as at distant sites (Milli-
kan et al, 1995). Multimodality treatment plays an increasingly
important role in the treatment of oesophageal cancer. Chemother-
apy with concurrent radiotherapy has been shown to be superior to
radiotherapy alone in patients with locoregional disease (Herskovic
et al, 1992). However, pre-operative treatment with chemotherapy
remains still investigational because a number of randomised
studies have provided conﬂicting results (Kok et al, 1997; Kelsen
et al, 1998; Clark, 2000). Chemotherapy can also be given for
palliation of symptoms and improvement of quality of life in
patients with metastatic disease (Spiridonidis et al, 1996; Ilson et
al, 1999).
Combination chemotherapy with cisplatin and 5-ﬂuorouracil
and/or etoposide or with bleomycin and vindesine has predomi-
nantly been used in patients with squamous cell carcinoma
(Kelsen et al, 1990; Kok et al, 1996; Bleiberg et al, 1997), yielding
response rates of 45–75% in patients with locoregional disease and
25–35% in patients (Enzinger et al, 1999).
Single agent paclitaxel has been tested in squamous cell and
adenocarcinomas of the oesophagus. Ajani et al (1994) reported
a response rate of 31% after treatment with paclitaxel
250 mg m
72 administered every 3 weeks in combination with
granulocyte colony-stimulating factor support. In combination
with cisplatin, also in a 3-week schedule, Kelsen et al (1997)
reported a response rate of 49% for patients with either locore-
gional or metastatic oesophageal cancer.
We previously performed a dose ﬁnding study with a ﬁxed
cisplatin dose (60 mg m
72) and increasing doses of paclitaxel
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(van der Gaast et al, 1999). The paclitaxel dose could be increased
to 200 mg m
72 without encountering dose limiting haematological
toxicity. However sensory neurotoxicity was dose limiting at pacli-
taxel dose levels 5190 mg m
72. The recommended dose for
further studies was paclitaxel 180 mg m
72 in combination with
cisplatin 60 mg m
72. In view of the response rate of 52% observed
in this dose ﬁnding study we performed a phase II study to further
conﬁrm the safety and activity of this bi-weekly regimen.
MATERIALS AND METHODS
Patients
Patients with histologically proven metastatic or unresectable
adenocarcinoma, undifferentiated- or squamous cell carcinoma of
the oesophagus or gastro-oesophageal junction area were eligible
for the study. Further eligibility requirements were: a life expec-
tancy of more than 12 weeks; age 418 years; WHO performance
status 0–2; written informed consent; adequate haematological,
renal and hepatic functions deﬁned as: granulocytes 51.56
10
9 l
71, platelets 5100610
9 l
71, total bilirubin 41.56upper
normal limit and creatinine 4120 mmol l
71. Patients were
required to have measurable or evaluable disease. Prior radiother-
apy was allowed if not involving more than 30% of the bone
marrow or was given within the 4 weeks prior to study entry.
The study was approved by the institutional ethics committee.
Drug administration
Paclitaxel 180 mg m
72 and cisplatin 60 mg m
72 were adminis-
tered intravenously every 2 weeks. After prehydration with at
least 1 l of normal saline, paclitaxel, diluted in 500 ml of normal
saline, was infused over 3 h and subsequently cisplatin was admin-
istered over 3 h followed by post-hydration over 24 h. All patients
received premedication with dexamethasone 20 mg given orally 12
and 6 h prior to the paclitaxel infusion. Thirty minutes before the
paclitaxel infusion, the patients received 10 mg dexamethasone,
2 mg clemastine and 50 mg ranitidine, all given i.v. Ondansetron
at a dose of 8 mg i.v. was given as anti-emetic prophylaxis. Patients
were retreated after 14 days when the granulocytes were
50.75610
9 l
71 and the platelets were 575610
9 l
71. When these
criteria were not met, treatment was postponed for 1 week. A dose
reduction was only made for patients with neutropenic fever; in
that case paclitaxel was reduced to 75% in subsequent courses.
Treatment assessment
Pre-treatment evaluations consisted of a complete medical history,
physical examination, complete blood cell count and serum
biochemistry, computerised tomography (CT) scan of the chest
and upper abdomen and ultrasonography of the supraclavicular
nodes when appropriate. Patients with the primary tumour in situ
were also evaluated by endoscopy. During treatment blood cell
counts were assessed every week and physical examination, toxicity
assessment and serum chemistry studies every 2 weeks. Toxicity
was graded and reported using NCI–CTC criteria (version 2).
For response evaluation the CT-scan, and also a ultrasonography
and endoscopy when appropriate, were repeated after the third
and sixth cycle and after discontinuation of therapy. Response
was evaluated using WHO criteria (World Health Organisation,
1979). A complete response (CR) required the disappearance of
all known disease, determined by two observations not less than
4 weeks apart, and for patients with the primary tumour in place
an endoscopic conﬁrmation of a complete response with normal
endoscopic biopsies. A partial response was deﬁned as a decrease
by at least 50% reduction in the sum of the products of the largest
perpendicular diameters in all measurable lesions or at least a 30%
reduction of the largest diameters in uni-dimensional disease
(evaluable disease) for at least 4 weeks. It is not necessary for all
lesions to have regressed to qualify for partial response, but no
lesion should have progressed and no new lesion should appear.
Stable disease was deﬁned as less than 50% decrease and less than
25% increase in tumour size. Progressive disease was a greater than
25% increase of one or more measurable lesions or the develop-
ment of new lesions.
The duration of response was deﬁned as lasting from the start of
treatment to documentation of the disease progression. Patients
with stable disease received up to a maximum of six cycles of treat-
ment. In patients achieving a partial or complete response, an
additional two cycles were allowed. Patients were followed for
survival and disease progression every 3 months until death.
Statistical considerations
Patient enrolment followed a ﬁve-step sequential design. If no
response was seen in the ﬁrst eight patients further accrual had
to be halted. Otherwise an additional six patients could be entered
and if at least two patients responded again six patients had to be
entered. In the fourth step 10 more patients were entered if at least
four responses were observed in the 20 patients that were treated.
Finally when 30 patients were treated the trial was continued with
an additional 20 patients if the observed number of responses was
at least 50%. Under this design there is only an 18% chance of
continuing the trial while the true response percentage is below
40%.
Actuarial survival was calculated using the method of Kaplan
and Meier.
RESULTS
Fifty-one patients were entered in this study. Patient characteristics
are listed in Table 1. All patients received at least three cycles of
chemotherapy and all were evaluable for toxicity and response. A
total of 286 cycles were administered (median six, range 3–8).
Nine patients received only three cycles. Three of these nine
patients had progressive disease and in ﬁve patients with stable
disease who had persistent dysphagia treatment was stopped and
these patients were palliated by oesophageal stenting. One patient
refused further treatment. Five of the remaining 42 patients did
not complete six cycles of therapy. Two patients were not able to
continue treatment after four cycles for reasons of toxicity mainly
consisting of fatigue, one patient developed a cerebrovascular acci-
dent and two patients had progressive disease after the fourth and
ﬁfth cycle, respectively. Seven patients who had achieved a partial
response received eight cycles of treatment.
Seventy-one chemotherapy cycles (25%) were delayed. In 19
(37%) patients there was no treatment delay; one, two or more
delays were required in respectively seven (14%), 11 (22%) and
14 (27%) patients. Sixty-ﬁve cycles in 25 (49%) patients were
delayed for 1 week because of a granulocyte count
50.75610
9 l
71. Four cycles were delayed for 1 week because of
infections without neutropenia, one cycle was delayed for 1 week
because of elevated liver-enzymes due to co-medication and one
cycle was delayed for 3 weeks in a patient who developed a
broncho-oesophageal ﬁstula 4 days after the start of chemotherapy.
The planned and achieved dose intensity were for cisplatin 30 and
26.4 mg m
72 per week, respectively, and for paclitaxel 90 and
79.3 mg m
72 per week, respectively.
Haematological toxicity
Neutropenia grade 3 and 4 were observed in 39 and 31% of
patients and in 23 and 10% of cycles, respectively. The nadir for
granulocytes usually occurred after the fourth or ﬁfth cycle of treat-
ment. Neutropenic infections were not observed. No
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tered in seven patients.
Non-haematological toxicity
Grade 1 sensory neurotoxicity was observed in 22 patients (43%)
and grade 2 in 10 patients (20%). Six of these in total 32 patients
had a complete resolution of sensory neurotoxicity and in 11
patients neurotoxicity partially subsided. Five patients developed
infections without neutropenia. Three of these patients were
admitted because of pneumonia, an urinary tract infection and
an infected subcutaneously implanted intravenous access device,
respectively. All patients recovered after treatment with antibiotics.
Two patients were admitted for gastro-intestinal toxicity. In total
ﬁve patients (10%) were hospitalised, three patients because of
treatment-related complications and two patients because of infec-
tions without neutropenia. There were no treatment-related deaths.
Other toxicities were usually mild and are listed in Table 2.
Responses
All 51 patients had measurable disease. The overall response rate
was 43%; 20 patients (39%) had a PR and two patients (4%)
had a CR. Stable disease was observed in 21 patients (41%) and
PD in eight patients (16%). Twenty-one of 22 responding patients
had bi-dimensionally measurable lesions and one patient had uni-
dimensionally evaluable disease. In 15 of 22 responding patients the
response was already documented after three courses of chemother-
apy. The duration of complete response was 7 months in a patient
with a local recurrence and lymph node metastases. The second
patient who had a complete response received additional radiother-
apy on the primary tumour and supraclavicular region and is still
disease free 29 months after start of treatment. The median dura-
tion of response (measured from start of treatment) in the patients
with a PR was 8 months (range 5–29+ months). Twenty-one
patients (41%) had stable disease with a median duration of 6.5
months. After a response to chemotherapy deﬁnitive local therapy
using either radiotherapy or surgery was attempted in nine patients
with either locally advanced disease or lymph node metastases
conﬁned to the celiac or supraclavicular region (M1a disease).
Two patients with an irresectable tumour underwent an oesopha-
geal resection, pathologic examination of the resected specimen
showed tumour free margins and these patients are disease free
20 and 28 months, respectively, after surgery. Seven patients with
M1a disease received radiotherapy at a dose of 50 Gy at the
primary tumour and involved lymph nodes; two of these patients
are disease free after 24 and 29 months, respectively. The overall
response rates for patients with adenocarcinoma, and squamous
cell carcinoma were 39 and 44%, respectively, and three of the four
patients with an undifferentiated carcinoma achieved an objective
response.
Survival
After a median follow-up of 32 months (range 1–32 months) 12
patients (24%) are still alive. The median actuarial survival in all
patients was 9 months (range 2–29+ months), with a one-year
survival rate of 43%. The median actuarial survival for responding
patients is 12 months (range 6–29+ months), compared to 7
months (range 2–31+ months) in non-responding patients.
DISCUSSION
Chemotherapy either alone or in combination with radiotherapy is
frequently used preoperatively in patients with resectable disease.
For patients with irresectable and/or metastatic disease chemother-
apy may offer a chance of both tumour regression and palliation of
symptoms. The effect of chemotherapy on survival in this group of
patients is unclear due to a lack of randomised phase III studies
comparing chemotherapy to best supportive care.
The combination cisplatin and 5-ﬂuorouracil is probably the
most frequently used combination in the treatment of oesophageal
cancer. Pre-operative treatment with this combination was toler-
ated well by patients with resectable disease in two large
randomised trials (Kelsen et al, 1998; Clark, 2000). However in
one of the few randomised studies performed in patients with
metastatic disease, the toxicity of this regimen appeared to be
severe (Bleiberg et al, 1997). In that trial 88 patients with meta-
static oesophageal cancer received either cisplatin in combination
with 5-ﬂuorouracil or cisplatin alone. In the cisplatin/5-ﬂuorouracil
arm there were 16% treatment related deaths, mostly due to
neutropenic sepsis, versus 0% in the cisplatin arm. Because of this
high incidence of treatment-related deaths the higher response rates
observed in the cisplatin/5-ﬂuorouracil arm most likely did not
translate in a signiﬁcant survival beneﬁt compared to treatment
with cisplatin alone. The difference in tolerability of chemotherapy
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Table 1 Patient characteristics (n=51)
Characteristic No. of patients (%)
Sex
Male 37 73
Female 14 27
Age (years)
Median 56
Range 32–78
WHO performance status
01 9 3 7
12 9 5 7
23 6
Weight loss (%)
0–5 13 25
5–10 15 29
410 23 45
Histology
Adenocarcinoma 31 61
Squamous cell carcinoma 16 31
Undifferentiated carcinoma 4 8
Prior therapy
Oesophagectomy 11 22
Radiotherapy 0 0
Extent of disease
Locally advanced/unresectable 5 10
Primary with distant metastases 35 69
Metastases after prior resection 11 22
Metastatic sites
Celiac/supraclavicular lymph nodes 38 75
Liver 13 25
Other 3 6
Table 2 Worst CTC grade non-haematological toxicities (n=51)
CTC grade (%)
012 3 4
Nausea 25 49 24 2
Vomiting 51 25 18 4 2
Diarrhoea 86 12 2
Mucositis 92 6 2
Neurotoxicity 37 43 20
Nephrotoxicity 96 4
Myalgia 65 33 2
Fatigue 60 20 20
Treatment with cisplatin and paclitaxel in oesophageal cancer
MB Polee et al
671
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 669–673between patients with resectable disease and patients with meta-
static disease could be explained by the fact that patients with
metastatic disease often have an impaired performance status,
substantial weight loss and co-morbidity.
Recently, several new agents such as the taxanes, irinotecan and
vinorelbine, have shown promising activity in the treatment of
oesophageal cancer. A further advantage of these new agents is that
they cause less mucosal toxicity compared to the combination of 5-
ﬂuorouracil and cisplatin with or without leucovorin.
In a previous study we demonstrated the feasibility of cisplatin
and paclitaxel administered in a treatment interval of 2 weeks
(van der Gaast et al, 1999). We were able to decrease the treatment
interval because we retreated the patients when their granulocytes
were above 750610
6 l
71 instead of the more common used
threshold for retreatment of 1500610
6 l
71. The safety of this
approach was conﬁrmed in the current study. Despite the fact that
70% of patients developed grade 3 or 4 neutrocytopenia, we did
not observe any episode of neutropenic fever. The achieved dose
intensity was for cisplatin 26.4 and for paclitaxel 79.3 mg m
72
per week.
Given the fact that most patients had metastatic disease the
treatment was well tolerated. Only ﬁve patients (10%) were hospi-
talised, three patients because of treatment-related complications
and two patients because of infections without neutropenia. In
general gastro-intestinal toxicity was mild and grade 2 mucositis
was observed in only two patients. Sensory neurotoxicity was the
predominant non-haematological side-effect: grade 1 and 2
occurred in, respectively, 43 and 20% of patients. In 19% of
patients with neurotoxicity we observed a complete resolution
and in 34% a partial improvement of neurotoxicity. The neuro-
toxicity observed with our bi-weekly regimen is comparable to
the neurotoxicity observed with regimens of cisplatin and paclitaxel
administered every 3 weeks. This may partly be explained by the
fact that neurotoxicity due to cisplatin is more correlated with
the cumulative cisplatin dose than with the dose-intensity (Hilkens
et al, 1995). The median cumulative dose of cisplatin in our study
was only 360 mg m
72.
The combination of cisplatin and paclitaxel with or without 5-
ﬂuorouracil was tested in patients with oesophageal cancer in three
other studies. Ilson et al (1998) treated 61 patients with the combi-
nation of paclitaxel 175 mg m
72 administered over 3 h on day 1,
cisplatin 20 mg m
72 days 1–5 and 5-ﬂuorouracil 1000 mg m
72
days 1–5; 48% of the patients had to be admitted for reasons of
toxicity. In a subsequent study 5-ﬂuorouracil was omitted and
paclitaxel 200–250 mg m
72 was administered over 24 h followed
by cisplatin 75 mg m
72 (Ilson et al, 2000). Cycles were repeated
every 3 weeks and all patients received granulocyte colony stimulat-
ing factor support. The toxicty in this study was also considerable
and 50% of the patients had to be hospitalised due to toxicity and
11% of the patients died from treatment-related complications. In
our study we used, expressed as administered dose per week, a
comparable dose of paclitaxel and a higher dose of cisplatin but
observed no severe toxicity. The fact that we administered pacli-
taxel over 3 h instead of 24 h might explain this difference (Eisen-
hauer et al, 1994). Petrasch et al (1998) treated 24 patients with
cisplatin 50 mg m
72 and paclitaxel 90 mg m
72 (3-h infusion),
also administered every 2 weeks. Using this, although compared
to our study, lower dose of paclitaxel they also observed no major
toxicities.
The response rate of 43% with a median duration of response of
8 months observed in our study is in line with the results reported
in the other studies with cisplatin and paclitaxel however with
substantial less toxicity. Of the 20 responding patients four
patients, who received additional radiotherapy or surgery, are still
disease free after a follow-up of 20–29 months.
In most studies on neo-adjuvant chemotherapy in patients with
oesophageal cancer response to chemotherapy is an important
prognostic factor. The tolerability of this bi-weekly regimen and
the high response rate observed in this study renders it attractive
for use in a neo-adjuvant setting. One of the reasons for the nega-
tive results of the Intergroup trial (Kelsen et al, 1998) comparing
chemotherapy followed by surgery to surgery alone in 440 patients
with resectable adenocarcinomas or squamous cell carcinomas,
might be the low response rate of 19% obtained with the combina-
tion of cisplatin and 5-ﬂuorouracil. Contrasting the negative results
of the Intergroup study are the results of a recently reported Medi-
cal Research Council (MRC) trial (Clark, 2000) randomising 802
patients to two pre-operative cycles of cisplatin and 5-ﬂuorouracil
followed by surgery or surgery alone, as well as one of our own
previous studies randomising 163 patients to pre-operative treat-
ment with cisplatin and etoposide followed by surgery or surgery
alone (Kok et al, 1997). In both studies survival was signiﬁcantly
better in patients receiving pre-operative chemotherapy.
Chemotherapy before surgery is therefore still an option for
patients with resectable oesophageal cancer. A randomised study
investigating the efﬁcacy of this bi-weekly cisplatin/paclitaxel regi-
men as a pre-operative treatment would therefore be appropriate.
In conclusion, cisplatin and paclitaxel administered every 2
weeks is an active combination in the treatment of patients with
advanced oesophageal cancer. The toxicity proﬁle of this regimen
compares favourable to that of previously used cisplatin-, and
paclitaxel-based regimens. Trials are underway evaluating this bi-
weekly regimen in a neo-adjuvant setting.
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